Dr. Melissa Anne Rubenstein, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 17051 Dallas Pkwy Ste 350, Addison, TX 75001 Phone: 214-702-0029 Fax: 214-382-3453 |
Melissa I Costner, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 17051 Dallas Pkwy Ste 350, Addison, TX 75001 Phone: 214-702-0029 Fax: 214-382-3453 |
Sonya Sunder Jagwani, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 17051 Dallas Pkwy Ste 350, Addison, TX 75001 Phone: 314-374-3614 |
News Archive
The "vegetable lamb" plant - once believed to bear fruit that ripened into a living baby sheep - produces substances that show promise in laboratory experiments as new treatments for osteoporosis, the bone-thinning disease. That's the conclusion of a new study in ACS' monthly Journal of Natural Products.
BD Diagnostics, a segment of BD, today announced that it obtained CE Marking for the BD MAX MRSA Assay to rapidly and accurately identify methicillin-resistant Staphylococcus aureus (MRSA) in patients.
Because they, like others, want to feel younger for longer, food companies and food researchers are striving to meet their needs. Increased amounts of nutritional supplements and antioxidants, including calcium, vitamin D and zinc, can slow the rate of age-related disease and increase the number of healthy years, according Jeffrey Blumberg, a nutrition scientist at Tufts University and speaker here at the Institute of Food Technologists Annual Meeting & Food Expo.
The Southeast Michigan Health Information Exchange announced today that it has won a $2,988,000 contract for an electronic medical records initiative from the Social Security Administration. This award comes to SEMHIE in partnership with its fiduciary, Southeastern Michigan Health Association and its project partners CNSI, The Object Management Group™, Computer Sciences Corporation and Oracle/Sun Microsystems.
Celldex Therapeutics, Inc. today announced the presentation of mature overall survival (OS) data for ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB).
› Verified 9 days ago